Evidence mapPaperPMID 42404626Full record

ReviewMaterials today. Bio2026

Nanomedicine targeting ECM stiffness: restoring mechanical homeostasis for cancer immunotherapy.

Mengru Yang, Hanran Jia, Ying Zhang, Xinru Shen, Yongmiao Zhang, Yiting Liu, Xintao Jia, Changxiang Yu, Zhidong Liu

Abstract readReview
In one paragraph

Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mengru YangSchool of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Hanran JiaSchool of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Ying ZhangState Key Laboratory of Chinese Medicine Modernization, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Xinru ShenSchool of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Yongmiao ZhangSchool of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Yiting LiuSchool of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Xintao JiaSchool of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Changxiang YuSchool of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Zhidong LiuSchool of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pathological stiffening of the extracellular matrix (ECM) in solid tumors drives immunosuppression and therapeutic resistance. However, non-specific ECM degradation has limited clinical benefit and risks promoting metastasis. To address this dilemma, this review proposes a paradigm shift from indiscriminate physical degradation toward spatiotemporally controlled reconstruction of mechanical homeostasis using smart nanomedicine, an approach that lies at the intersection of materials science, cancer biology, and immunotherapy. We first concisely outline how aberrant ECM stiffness drives a vicious cycle of physical immune exclusion, mechanotransduction-mediated immune reprogramming, and reciprocal fibrotic activation. We then critically analyze how advanced nanomedicine platforms can. achieve precise ECM modulation without off-target toxicity. Central to this approach is the "mechano-therapeutic window", an optimal stiffness range that maximizes immune infiltration and therapy sensitization without provoking metastatic risk. Furthermore, we highlight the "priming" strategy, wherein nanomedicine-mediated ECM softening serves as an upstream step to synergistically enhance subsequent immunotherapy, chemotherapy, and radiotherapy, as well as other emerging therapies. Finally, we outline future directions, including the development of adaptive delivery systems that sense and adapt to stiffness dynamics in real-time. By shifting focus from indiscriminate degradation to intelligent mechanical homeostasis, this framework aims to improve cancer immunotherapy outcomes in desmoplastic solid tumors.

Indexed as

Extracellular matrix stiffnessMatrix remodelingMechanical homeostasisNanomedicineTumor immunosuppression

Identifiers

PMID42404626
PMCPMC13332124

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.